Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults
Sean M. Amberg, Benjamin Snyder, Portia A. Vliet-Gregg, Eric J. Tarcha, Jeff Posakony, Kristin Bedard, Alison E. Heald
Abstract
= 6). LHF-535 was well tolerated in both studies. Treatment-emergent adverse events were more frequent in placebo recipients than in LHF-535 recipients in both studies. LHF-535 exhibited rapid absorption, a long half-life, and exposures predicted to suppress viral replication.
Topics & Concepts
Lassa feverPharmacokineticsMedicinePharmacologyLassa virusArenavirusVirologyImmunologyVirusImmune systemCD8Lymphocytic choriomeningitisViral Infections and Outbreaks ResearchDisaster Response and ManagementBacillus and Francisella bacterial research